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Introduction 
Symptom control for people with cancer improves quality of life. Haloperidol is a key 
drug in palliative care and is frequently used for the treatment of delirium, nausea and 
vomiting.[1] Haloperidol, a butyrophenone, is a more potent D2 receptor antagonist 
than other antiemetics such as prochlorperazine, olanzapine or chlorpromazine.  
 
The adverse events associated with haloperidol are like those of the phenothiazines, 
except that haloperidol potentially causes less sedation and hypotension. However, 
haloperidol is more strongly associated with extrapyramidal symptoms especially 
compared with newer drugs such as quetiapine or risperidone, and patients with 
Parkinson disease or Lewy body dementia may be more sensitive to its adverse 
events.[2] Haloperidol is inexpensive and has several routes of administration. Only a 
few studies focus on patients with life-limiting illnesses. The aim of this study was to 
determine whether the doses of haloperidol used in palliative care cause immediate and 
short-term harms and, if so, what is their severity?  
 
Material and Methods 
This study was a post hoc analysis conducted on three RCTs (studies 1,2 (nausea), 3 
(delirium)) [3-5] and two international collaborative phase IV consecutive cohort studies 
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(studies 4 (nausea), 5 (delirium)), [6,7] which have been described previously. Severity of 
immediate and short term harms were assessed using the National Institutes of Health 
Common Terminology Criteria for Adverse Events (NCI CTCAE). [8,9] Nausea was 
graded by clinicians using verbal descriptors (none; mild; moderate; or severe). Items and 
evaluation times for harms differed between studies. Most frequently, routine data were 
collected at baseline and days 1, 2 and 7.   
 
This study reports the number and percentage of participants with severity ≥3 grade and 
symptom deterioration ≥1 point from baseline in symptoms of interest. Harms in all five 
studies could also be reported on an ad hoc basis.   
 
Descriptive statistics are used in this study, with categorical variables summarized as 
frequency and percentages, and continuous variables with median and interquartile 
ranges (IQR). 
 
This study is generated from secondary use of de-identified data that have been 
aggregated. All participants in studies 1-3 gave written informed consent and the studies 
were approved by the relevant Human Research Ethics Committees before recruitment 
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commenced. For studies 4 and 5, these were capturing routine data after the clinician had 
made the decision to commence haloperidol for the indication being studied. Sites had 
waivers of consent for these de-identified clinical data and ethics approvals or waivers 
depending on the country in which the data were collected.  
Results 
Patients’ characteristics 
The clinical and demographic data of the 494 subjects are shown in Table 1. In the 
current study, the most subjects (90 %) had advanced metastatic cancer (94 % in studies 
1-3 (phase III) and 87% in Phase IV studies, respectively). The median age was 73 years 
old (IQR: 64.5-81) and median Australia-modified Karnofsky Performance Scale 
(AKPS) [10] was 40 (IQR: 30-50), indicating that many subjects required ‘‘considerable 
assistance and frequent medical care.''  AKPS in phase III studies was better than the 
phase IV studies. The median daily dose of haloperidol was 1.5mg (day 1), 2.0mg (day 
2), 1.5mg (day 7) in oral or parenterally preparations.  
Harms 
Potential harms from treatment with haloperidol and the clinical responses to address 
those symptoms are shown in Table 1. Harm in this study was defined as a one-point 
deterioration from baseline in NCI CTCAE criteria for the relevant symptom. Frequently 
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reported harms were somnolence (1.9, 2.0, and 2.9 % on day1, 2 and 7, respectively) and 
treatment emergent harms ≥ grade 3 cumulatively by day 7 were seen in 5.6 % patients 
in phase III studies. In terms of rigidity including extrapyramidal symptoms, there were 
no reports of any events graded ≥3. Even when including harms graded 1 or 2, one event 
was reported on each of days 1, 2 and 7.  
 
Discussion 
To our knowledge, this study is the first study to evaluate the harms of haloperidol in 
palliative care. This study was a post hoc analysis conducted on three adequately 
powered, randomised, controlled trials and two consecutive cohort studies where all 
data were collected prospectively searching for specific adverse events from haloperidol 
that had previously been identified in the literature.  
 
The study is limited to the immediate and short-term harms from the introduction of 
haloperidol, but the most remarkable thing is how well the medication is tolerated. 
Other harms or worsening of emerging adverse events will occur over time, and further 
research is required to elucidate these clinical effects. The doses used tend to be lower 
(≤2mg/day) than many reports in the literature from contemporary practice.  
 
Taking these limitations into consideration, we believe our results support the use of low 
dose haloperidol in palliative care settings for nausea and vomiting (given the study in 
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delirium was strongly negative and consistent with the findings of several systematic 
reviews).  
 
In conclusion, low dose haloperidol was tolerated well in the immediate and short term 
in a frail population of people mostly with advanced cancer. Further work should be 
done to follow a similar cohort of patients for a longer period of time with prospective 
bespoke data collection to map the emergence of any mid- and long-term harms.  
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Table 1. Comparison of the characteristics of participants in phase III clinical studies for 
symptom control (n=226) with the phase IV palliative care populations (n=268) 
Item 
Phase IV 
pharmacovigilance 
population (n = 268) 
Phase III (n = 
226) 
Age, Median (IQR) 73.0 (65-81) 73.0 (64-80) 
Sex, n (%) 
  
 
Men 
  
130 (48.5) 95 (42.0) 
 
Women 
  
137 (51.1) 127 (56.2) 
 Missing   1(0.4) 4 (1.8) 
Diagnosis, n (%)   
 Cancer   234 (87) 211(94) 
 
End-Stage Disease (Cardiac, Renal, 
Hepatic, Respiratory)   14 (5) 2 (1) 
 Neurodegenerative Disease   3 (1) 3 (1) 
 Other   17 (7) 10 (4) 
AKPS, Median (IQR) 40 (30-50) 50 (40-60) 
Symptom Control   
 Nausea and/or Vomiting   150 145 
 Delirium   118 81  
Treatment emergent adverse events ≥ grade 3 
cumulatively by day 7    
 Anorexia   0 0 
 Constipation   1 (1.0) 0 
 Dizziness   0 1 (0.8) 
 Hypertension   0 0 
 Rigidity   0 0 
 Somnolence   0 12 (5.6) 
 Dry mouth   1 (1.0) 0 
 Extrapyramidal Reaction   0 0 
 Diarrhoea    0 0 
 Hypotension   0 0 
 
